Ora®, Inc. has been retained by ProQR Therapeutics to provide mobility test services using the Ora-VNC™ for the QR-110 development program for Leber's Congenital Amaurosis Type 10

News provided by

Nov 13, 2018, 10:00 ET

ANDOVER, Mass., Nov. 13, 2018 /PRNewswire/ -- Ora^® Inc. has been retained by ProQR Therapeutics to provide standardized mobility test services for ProQR's Phase 3 development program for Leber's Congenital Amaurosis Type 10. On September 5^th 2018, ProQR Therapeutics announced positive interim results from the Phase 1/2 Clinical Trial of QR-110, a trial managed by Ora and featuring Ora's VNC^™ mobility courses, noting "QR-110 demonstrated rapid and sustained improvement in vision in patients with LCA10, as measured by visual acuity and the mobility course performance." https://ir.proqr.com/news-releases/news-release-details/proqr-announces-positive-interim-results-phase-12-clinical-trial. Following these positive results, ProQR Therapeutics and Ora Inc. have entered into an agreement to use the Ora-VNC^™ mobility courses in ProQR's pivotal program assessing QR-110 oligonucleotide therapy for treatment of Leber's Congenital Amaurosis Type 10.

About Ora-VNC^™ mobility course

To address the need for functional vision endpoints in Inherited Retinal Diseases (IRDs) and dry age-related macular degeneration (dry AMD) clinical studies, Ora developed a series of mobility courses (Ora-VNC™ (Visual Navigation Challenge)). These obstacle courses are customized to each retinal disease and are responsive to a wide range of visual acuities, visual fields, and light sensitivities. ''The team at Ora has partnered across the industry to evaluate innovative IRD therapies in specifically tailored Ora-VNC™ mobility courses. We are proud to support both our pharmaceutical and device partners develop potential vision-saving products for patients that have been left with limited options for far too long," said David A. Hollander, MD, Chief Medical Officer at Ora.

These courses allow for clinically meaningful assessments of visual function through immersion of patients in a 360-degree visual challenge environment. Ora has installed their Ora-VNC^™ mobility courses at 15 leading IRD research sites worldwide with additional installations planned for 2019.

About Ora^®, Inc.

Ora is the world's leading full-service ophthalmic CRO and product development firm with offices in the United States, the United Kingdom, Australia and Japan. Over the past 40 years, we have proudly helped our clients earn more than 45 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts and R&D professionals to maximize the value of new product initiatives. For more information, please visit www.oraclinical.com

For questions on the release please contact:
Jeanne Taylor Hecht
Board of Directors, Ora, Inc.
[email protected]
+1.919.601.8139

SOURCE Ora, Inc.